Jason D Thorpe

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Effects of blood collection conditions on ovarian cancer serum markers
    Jason D Thorpe
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 2:e1281. 2007
  2. pmc Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study
    Garnet L Anderson
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, M3 A410, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 102:26-38. 2010
  3. pmc Potential role of HE4 in multimodal screening for epithelial ovarian cancer
    Nicole Urban
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 103:1630-4. 2011
  4. pmc Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening
    Charles W Drescher
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Cancer Prev Res (Phila) 5:1015-24. 2012
  5. pmc Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery
    Sharon J Pitteri
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 4:e7916. 2009
  6. pmc Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA
    Nathalie Scholler
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104 6069, USA
    Clin Cancer Res 14:2647-55. 2008
  7. pmc Systematic evaluation of candidate blood markers for detecting ovarian cancer
    Chana Palmer
    Canary Foundation, Scientific Programs, San Jose, California, United States of America
    PLoS ONE 3:e2633. 2008

Collaborators

Detail Information

Publications7

  1. pmc Effects of blood collection conditions on ovarian cancer serum markers
    Jason D Thorpe
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 2:e1281. 2007
    ..By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies...
  2. pmc Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study
    Garnet L Anderson
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, M3 A410, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 102:26-38. 2010
    ..Except for CA125, their behavior in the prediagnostic period has not been evaluated...
  3. pmc Potential role of HE4 in multimodal screening for epithelial ovarian cancer
    Nicole Urban
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 103:1630-4. 2011
    ..03). Serum HE4 levels were found to increase with age and smoking status, suggesting that a longitudinal algorithm might improve its performance...
  4. pmc Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening
    Charles W Drescher
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Cancer Prev Res (Phila) 5:1015-24. 2012
    ..Identification of a first-line test that does substantially better than CA125 and has similar costs is required for screening to reduce ovarian mortality by at least 25% and be reasonably cost-effective...
  5. pmc Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery
    Sharon J Pitteri
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 4:e7916. 2009
    ..The goal of this work is to evaluate the utility of an integrative strategy using these two approaches for biomarker discovery...
  6. pmc Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA
    Nathalie Scholler
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104 6069, USA
    Clin Cancer Res 14:2647-55. 2008
    ..Mouse monoclonal antibodies (mAb) and polyclonal antibodies (pAb) are commonly used, but because their production is lengthy and costly, recombinant antibodies are emerging as an attractive alternative...
  7. pmc Systematic evaluation of candidate blood markers for detecting ovarian cancer
    Chana Palmer
    Canary Foundation, Scientific Programs, San Jose, California, United States of America
    PLoS ONE 3:e2633. 2008
    ..We evaluated the performance of a set of candidate blood markers and combinations of these markers in detecting serous ovarian cancer...